All three assays in the family are designed to identify key biomarkers in guidelines and clinical trials.
Assess key cancer biomarkers from FFPE tumor tissue with the TruSight Oncology 500 Assay.
Batch up to 192 samples at a time while using the same biomarkers and tissue type as the TruSight Oncology 500 assay.
Analyze circulating tumor DNA from plasma with the TruSight Oncology 500 ctDNA assay.
High concordance of TMB analysis between TruSight Oncology 500 and TruSight Oncology 500 High Throughput.
High concordance of MSI analysis between TruSightOncology 500 and TruSight Oncology 500 High Throughput.
High concordance of VAF between TruSightOncology 500 and TruSight Oncology 500 High Throughput.
Fusion and splice variants as detected using TruSight Oncology 500 o the NextSeq 500 System. Numeric values represent the number of supporting reads for each sample at the indicated RNA input amount. Cut-off value for RNA fusions = 5; cut-off value for splice variants = 10.
Content for TruSight Oncology 500 and TruSight Oncology 500 High-Throughput includes key guideline biomarkers for multiple cancer types, plus current and emerging pan-cancer biomarkers such as TMB, MSI, NTRK1, NTRK2, and NTRK3.
* Based on PierianDx Clinical knowledgebase, as of March 2020